Discussion Guide — Chapter 33

Six prompts, with what to listen for. Each runs 10–15 minutes.

1. "The receptor pharmacology was never the problem — evolution had optimized it. What was engineered was survival."

Ask them to unpack this and then to say whether it generalizes.

Listen for: recognition that the hormone was already excellent at its target, and that the drug developers were not improving on evolution but repurposing a molecule for a job it was never selected for. Listen for the good version: students who notice that GLP-1's brevity is a specification met rather than a flaw — a meal signal must terminate. Redirect if: the conversation slides into "evolution is perfect," which is not the claim; the claim is narrower and about this receptor-ligand pair.

2. A residue in every dose of an approved medicine exists to serve the analytical chemistry department. Is that good drug design or a compromise?

The Lys34→Arg question. Let it be uncomfortable.

Listen for: the recognition that a drug which cannot be manufactured reproducibly does not exist, so the dichotomy may be false. Listen for the sophisticated version: students who ask what the alternative would have been — accept a mixture of attachment isomers, or separate them at scale — and who notice that both alternatives also affect patients, just less visibly. Watch for: the assumption that anything not benefiting the patient is a cost to the patient. It usually isn't.

3. How would you know a peptide got into a cell?

The §33.3 methods question, run as a design exercise rather than a recall question.

Listen for: the fixation artifact; the distinction between "inside a cell" and "in the cytosol"; endosomal escape as the rate-limiting step. Best answers reach for a functional readout — does the peptide do the thing that engaging its intracellular target should do, dose-dependently, abolished by a target mutation. Redirect if: students propose ever-fancier microscopy. The point is that imaging alone is the wrong instrument for this question.

4. Was PEGylation abandoned, displaced, or retired?

Run this before assigning Case Study 33.2 if you can; the pre-discussion misdiagnosis makes the case study land better.

Listen for: the three-part test — were the findings published openly and by whom, did a better alternative arrive in the same window, is the technology still in use where the trade-off is acceptable. Listen for the strong move: students who note that much of the damaging literature came from people whose own programs it harmed. Watch for: the conspiracy reflex, and for its mirror image — the student who insists nothing was ever wrong with PEG. Both are lazy. The honest position is that early confidence in inertness was too confident and nothing was hidden.

5. Fixed ratio or tunable ratio — which architecture would you bet on, and what would change your mind?

Tirzepatide vs. CagriSema, run as a design decision rather than a clinical comparison.

Listen for: the specific trade-offs — one PK profile versus two that can diverge, one immunogenicity program versus two, adjustable ratio versus a new molecule. Listen for the crucial distinction: a head-to-head trial result is evidence about two products, not a verdict on two architectures, because the comparison confounds architecture with the particular ratio, molecules, and doses studied. If the room converges too quickly, ask what happens when antibodies develop against one component of a coformulation but not the other.

6. A clinic advertises peptides "molecularly optimized for enhanced potency." What do you ask?

The applied version, and the best closer. Give them two minutes to write three questions before anyone speaks.

Listen for: questions that map to the four goals — which exit does this close, what is the measured half-life and where does that number come from, "more effective" compared to what, at what exposure. Listen for the Field 4 instinct: what was changed relative to the native sequence, and if the answer is "nothing," what is the half-life and does the way it is used reconcile with that number. The moment worth waiting for is when someone realizes they can evaluate the claim without any clinical evidence at all — which is the same move Chapter 1 taught with digestion, now running at a higher level. Name it when it happens.